Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo Acquires Zepharma
April 10, 2006
- Astellas, Toyama Ink Licensing Agreement on New Quinolone T-3811
April 10, 2006
- Market for Bio-derived Materials to Grow 54% by 2010: Fuji-Keizai
April 10, 2006
- Astellas Switches to Disease-Based 2-Line Marketing System
April 10, 2006
- SELF-MEDICATION NEWS IN BRIEF
April 10, 2006
- Deloitte Touche Tohmatsu Forms "Pharma Team" to Support Life Science Industry
April 10, 2006
- OPINION
April 10, 2006
- Janssen Pharm. Reports 7th Year of Double-Digit Growth
April 10, 2006
- HUMAN RESOURCES NEWS IN BRIEF
April 10, 2006
- Yoh Narimatsu Appointed President and CEO of Quintiles Japan
April 10, 2006
- MEDICAL DEVICE NEWS IN BRIEF
April 10, 2006
- Astellas Licenses Anti-Human Osteopontin Antibodies from IBL
April 3, 2006
- Eli Lilly to Enter GP Market with Tadalafil: President Crenshaw
April 3, 2006
- Toyama's T-705 Effective Against Avian Flu in Early Testing
April 3, 2006
- US Subsidiaries of Daiichi, Sankyo to Integrate Operations
April 3, 2006
- Janus Initiates PII Trial of Topical Herpes Zoster Treatment in US
April 3, 2006
- Worldwide Production of Tamiflu Expanded to 400 Mil. Treatments: Chugai
April 3, 2006
- CytoPathfinder, Santen to Do Joint Research for Ophthalmic Drugs
April 3, 2006
- BUSINESS NEWS IN BRIEF
April 3, 2006
- PMDA to Propose Policy Regarding Int'l Joint Clinical Trials
April 3, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…